RECRUITING

Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The central hypothesis of ROMA:Women is that the use of multiple arterial grafting (MAG) will improve clinical outcomes and quality of life (QOL) compared to single arterial grafting (SAG). The specific aims of ROMA:Women are: Aim 1: Determine the impact of MAG vs SAG on major adverse cardiac and cerebrovascular events in women undergoing coronary artery bypass grafting (CABG). The investigators will compare major adverse cardiac and cerebrovascular events (death, stroke, non-procedural myocardial infarction, repeat revascularization, and hospital readmission for acute coronary syndrome or heart failure) in a cohort of 2,300 women randomized 1:1 to MAG or SAG. Differences by important clinical and surgical subgroups (patients younger or older than 70 years, diabetics, racial and ethnic minorities, on vs off pump CABG, type of arterial grafts used) will also be evaluated. The women enrolled in the ongoing ROMA trial (anticipated to be approximately 690) will be included in ROMA:Women, increasing efficiency and reducing enrollment time. Hypothesis 1.0. MAG will reduce the incidence of major adverse cardiac and cerebrovascular events. Hypothesis 1.1. The improvement with MAG will be consistent across key subgroups. Aim 2: Determine the impact of MAG vs SAG on generic and disease-specific QOL, physical and mental health symptoms in women undergoing CABG. The investigators will compare generic (SF-12, EQ-5D) and disease-specific (Seattle Angina Questionnaire) QOL and physical and mental health symptoms (PROMIS-29) in a sub-cohort of 500 women randomized 1:1 to MAG or SAG (including those enrolled in ROMA:QOL). Differences by important subgroups (as defined above) will also be evaluated. Hypothesis 2.0. MAG will improve generic and disease-specific QOL compared to SAG. Hypothesis 2.1. MAG will improve physical and mental health symptoms compared to SAG. Hypothesis 2.2. The improvement with MAG will be consistent across key subgroups.

Official Title

Randomized Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women (ROMA:Women) Trial

Quick Facts

Study Start:2023-04-17
Study Completion:2030-03
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04124120

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:FEMALE
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Women patients ≥18 years old.
  2. 2. Isolated coronary artery bypass grafting.
  3. 3. Primary (first time) cardiac surgery procedure.
  4. 4. Significant disease of the left main coronary artery or of the left anterior descending and the circumflex coronary system with or without disease of the right coronary artery.
  1. * Male gender
  2. * Single graft
  3. * Emergency operation
  4. * Myocardial infarction within 72 hours of surgery
  5. * Left ventricular ejection fraction \< 35%
  6. * Any concomitant cardiac or non-cardiac procedure
  7. * Previous cardiac surgery
  8. * Preoperative severe end-organ dysfunction (dialysis, liver failure, respiratory failure), cancer or any co-morbidity that reduces life expectancy to less than 5 years.
  9. * Inability to use the saphenous vein or to use both radial and right internal thoracic arteries
  10. * Anticipated need for coronary thrombo-endarterectomy
  11. * Planned hybrid revascularization

Contacts and Locations

Study Contact

Mario Gaudino, Prof/PhD/MD
CONTACT
212.746.1812
mfg9004@med.cornell.edu
Stephen Fremes, Prof/MD
CONTACT
1 416 480 6073
stephen.fremes@sunnybrook.ca

Principal Investigator

Mario Gaudino, Prof/PhD/MD
PRINCIPAL_INVESTIGATOR
Weill Medical College of Cornell University
Stephen Fremes, MD
PRINCIPAL_INVESTIGATOR
Sunnybrook Health Sciences Centre
Ruth Masterson Creber, RN, PhD
PRINCIPAL_INVESTIGATOR
Columbia University
C. Noel Bairey Merz, MD
PRINCIPAL_INVESTIGATOR
Cedars-Sinai
Karla Ballman, PhD
PRINCIPAL_INVESTIGATOR
Weill Medical College of Cornell University
Sean O'Brien, PhD
PRINCIPAL_INVESTIGATOR
Duke University

Study Locations (Sites)

Cedars-Sinai Medical Center
Los Angeles, California, 90048
United States
Pomona Valley Hospital Medical Center
Pomona, California, 91767
United States
University of California, San Francisco
San Francisco, California, 94118
United States
University of Colorado
Aurora, Colorado, 80045
United States
Hartford Hospital
Hartford, Connecticut, 06106
United States
Yale University Hospital
New Haven, Connecticut, 06510
United States
Emory University
Atlanta, Georgia, 30322
United States
University of Chicago
Chicago, Illinois, 60637
United States
University of Iowa
Iowa City, Iowa, 52242
United States
Johns Hopkins University
Baltimore, Maryland, 21218
United States
Baystate Health
Springfield, Massachusetts, 01199
United States
University of Massachusetts Chan Medical School
Worcester, Massachusetts, 01655
United States
University of Michigan
Ann Arbor, Michigan, 48104
United States
Corewell Health William Beaumont University Hospital
Royal Oak, Michigan, 48073
United States
Washington University in St. Louis
St Louis, Missouri, 63110
United States
Nebraska Heart Hospital
Lincoln, Nebraska, 68526
United States
Methodist Physicians Health
Omaha, Nebraska, 68118
United States
University of Nebraska Medical Center
Omaha, Nebraska, 68198
United States
Englewood Health
Englewood, New Jersey, 07631
United States
Newark Beth Israel Medical Center
Newark, New Jersey, 07112
United States
The Valley Hospital
Ridgewood, New Jersey, 07450
United States
NewYork-Presbyterian Brooklyn Methodist Hospital
Brooklyn, New York, 11215
United States
Weill Cornell Medicine
New York, New York, 10021
United States
Columbia University Medical Center
New York, New York, 10032
United States
Lenox Hill Hospital
New York, New York, 10075
United States
New York Presbyterian Queens
Queens, New York, 11355
United States
Duke University
Durham, North Carolina, 27710
United States
East Carolina University
Greenville, North Carolina, 27858
United States
Wake Forest University
Winston-Salem, North Carolina, 27106
United States
Cleveland Clinic Foundation
Cleveland, Ohio, 44195
United States
Ohio State University
Columbus, Ohio, 43210
United States
Genesis Healthcare System
Zanesville, Ohio, 43701
United States
University of Pennsylvania
Philadelphia, Pennsylvania, 19104
United States
Allegheny General Hospital
Pittsburgh, Pennsylvania, 15212
United States
Lankenau Medical Center
Wynnewood, Pennsylvania, 19096
United States
Rhode Island Hospital
Providence, Rhode Island, 02903
United States
Baylor Scott & White Research Institute
Dallas, Texas, 75204
United States
The University of Texas Medical Health Branch at Galveston
Galveston, Texas, 77550
United States
Baylor College of Medicine
Houston, Texas, 77030
United States
UT Health San Antonio
San Antonio, Texas, 78229
United States
University of Utah
Salt Lake City, Utah, 84132
United States

Collaborators and Investigators

Sponsor: Weill Medical College of Cornell University

  • Mario Gaudino, Prof/PhD/MD, PRINCIPAL_INVESTIGATOR, Weill Medical College of Cornell University
  • Stephen Fremes, MD, PRINCIPAL_INVESTIGATOR, Sunnybrook Health Sciences Centre
  • Ruth Masterson Creber, RN, PhD, PRINCIPAL_INVESTIGATOR, Columbia University
  • C. Noel Bairey Merz, MD, PRINCIPAL_INVESTIGATOR, Cedars-Sinai
  • Karla Ballman, PhD, PRINCIPAL_INVESTIGATOR, Weill Medical College of Cornell University
  • Sean O'Brien, PhD, PRINCIPAL_INVESTIGATOR, Duke University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-04-17
Study Completion Date2030-03

Study Record Updates

Study Start Date2023-04-17
Study Completion Date2030-03

Terms related to this study

Additional Relevant MeSH Terms

  • Heart Diseases
  • Coronary Artery Disease
  • Coronary Artery Bypass Grafting